COMMUNIQUÉS West-GlobeNewswire
-
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
29/07/2026 -
SciSparc: Subsidiary NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company
29/07/2026 -
TOMI Environmental Solutions Reaffirms $12 Million Revenue Guidance for Fiscal 2026 and Confirms $35 Million Sales Pipeline with $8.6 Million in Advanced Stages
29/07/2026 -
MediWound to Report Second Quarter 2026 Financial Results
29/07/2026 -
Walmart Canada, Associates and Customers Raise $7.2 Million to Support Children’s Hospitals Across Canada
29/07/2026 -
RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET
29/07/2026 -
BIOT to Launch Indonesia’s First Subscription-Model Beauty Clinics Under Its Own Japanese Brand “GENRÊVER CLINIC” — Building a Recurring-Revenue Platform in One of Asia’s Fastest-Growing Aesthetics Markets
29/07/2026 -
Hyperion DeFi Schedules First Quarter Earnings Call for Wednesday, August 12 at 5:00 p.m. ET
29/07/2026 -
Anika Reports Second Quarter 2026 Financial Results
29/07/2026 -
Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration
29/07/2026 -
BrainsWay to Report Second Quarter 2026 Financial Results on August 12, 2026
29/07/2026 -
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
29/07/2026 -
Axogen, Inc. Reports Second Quarter 2026 Financial Results
29/07/2026 -
Lumexa Imaging Announces Second Quarter 2026 Earnings Conference Call Date
29/07/2026 -
TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update
29/07/2026 -
Atavistik Bio Appoints Habib Dable to its Board of Directors
29/07/2026 -
Biodexa lance des activités de soutien aux patients atteints de polypose adénomateuse familiale (PAF) et aux centres de traitement en France
29/07/2026 -
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS
29/07/2026 -
Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe
29/07/2026
Pages